What is ovarian cancer in phase 3?

The woman has ovarian cancer in stage 3 when the disease is present, is one or both ovaries and abdominal lymph nodes or has spread to the pelvic area. In ovarian cancer in Stage 3, there are three subcategories based on how far the disease has spread and how large tumor implants are. Several tests including pelvic examination, ultrasound and tissue sample and blood analysis are performed to determine the patient's cancer stage. Once the phase is determined, it is possible to discuss available treatment options and a five -year survival rate. The AJCC/TNM system determines the stages of ovarian cancer describing the extent of the primary tumor and the absence or the presence of distant metastases and metastases to nearby lymph nodes. There are four stages of ovarian cancer; Once cancer exceeds the ovaries, it will be introduced as two, three or four.

the first three phases of the ovarian cancer are divided into tRome categories marked a, b and c. If ovarian cancer in stage 3 falls into the subcategory A, then in the abdomen is not visible cancer with the naked eye or in nearby lymph nodes. The subcategory B classification suggests that there is no cancer in nearby lymph nodes, but tumor deposits that are less than 0.75 inches (two centimeters) are visible in the abdomen. When cancer is in nearby lymph nodes and visible abdominal cancer deposits exceed 0.75 inches (2 cm), the disease will be listed as a subcategory c.

The

staging process usually begins either by surgery, or by tests such as ultrasound, computed tomography or magnetic resonance. During the surgery, the surgery examines the abdomen for visible signs of cancer and often collects tissue and fluid avzorky. If cancer is visible, the surgeon can immediately remove it. Display tests are less invasive to find out whether cancer has expanded behind the ovaries.

Staging determines how widespread patient cancer is. During the surgery, ovarian cancer may be presented if other tests cannot apparently indicate how far the disease has spread. The exact performance is essential because different treatment and forecasts are associated with each phase of ovarian cancer. A faulty performance may result in incorrect treatment and inaccurate forecast.

Patients who wish to make informed decisions on their treatment should ask their treatment teams to explain in detail the production. The staging procedure should be thorough and the phase should be determined after the operation. The five -year survival rate in patients with ovarian cancer in Stage 3 ranges from 20 to 50 percent, but such statistics are only predictive; The case of each patient is unique.